## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

FANTO et al

Atty. Ref.: 2801-36

Serial No. 09/533,381

Group: 1621

Filed: March 26, 2001

Examiner: Barts

For: 2-AMINOTETRALINES AND PHARMACEUTICAL COMPOSITIONS FOR THE

PREVENTION AND THERAPEUTIC TREATMENT OF INFLAMMATORY

AND/OR AUTOIMMUNE PATHOLOGIES

\* \* \* \* \* \* \* \*

December 19, 2001

Assistant Commissioner for Patents Washington, DC 20231

Sir:

## RESPONSE

Responsive to the Official Action dated December 7, 2001, Paper No. 4, and requirement for restriction presented in it, applicants elect the subject matter of Group II, namely, claims 9, 12 and 15 drawn to a method of preventing or treating septic shock. Specific embodiments of the invention are disclosed in the data given on pages 40-47 of the specification.

Responsive to item 4 of the Official Action, the elected single disclosed species is (R,S)-2-amino-6-fluoro-7-methyltetraline hydrochloride (ST 1275) which is disclosed in the specification at page 6, line 12, and otherwise identified throughout the specification and data as ST 1275.

This response is made with traverse. The compounds disclosed in the present application are effective in counteracting the aetiopathogenetic role of inflammatory cytokines (see page 1, first paragraph). Inflammatory cytokines are responsible for septic

FANTO et al

Serial No. 09/533,381

shock and inflammatory and/or autoimmune pathologies (see page 1, last paragraph to page 2, first paragraph).

Examination on the merits is awaited taking into account the Information Disclosure Statement filed March 26, 2001.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By:

Arthur R/Crawford Reg. No. 25,327

ARC:lsp 1100 North Glebe Road, 8th Floor Arlington, VA 22201-4714

Telephone: (703) 816-4000 Facsimile: (703) 816-4100